Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract 2573: Investigation of factors involved in the hypersensitivity to KP1339-treatment

Beatrix Alte, Christine Pirker, Thomas Mohr, Kushtrim Kryeziu, Bernhard K. Keppler, Petra Heffeter and Walter Berger
Beatrix Alte
Medical University of Vienna, Vienna, Austria;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Pirker
Medical University of Vienna, Vienna, Austria;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Mohr
Medical University of Vienna, Vienna, Austria;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kushtrim Kryeziu
Medical University of Vienna, Vienna, Austria;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernhard K. Keppler
University of Vienna, Institute of Inorganic Chemistry, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Petra Heffeter
Medical University of Vienna, Vienna, Austria;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter Berger
Medical University of Vienna, Vienna, Austria;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2015-2573 Published August 2015
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA

Abstract

The ruthenium-based compound KP1339 (trans-(tetrachlorobis(1H-indazole)ruthenate(III)), which is currently in Phase I/II trial, is already known for its promising anticancer activity. In course of a recent screening using diverse cancer cell lines of different origin (n = 25), a small subgroup with exceptional sensitivity to KP1339-treatment was discovered. The aim of the here presented study was to identify factors that underlie this sensitivity or which are connected to resistance to KP1339. Due to the fact that KP1339 comprises a metal center, interpretations of it's mode of action tend towards either generation of ROS or DNA binding. To avoid a biased approach, whole genome expression arrays were performed with mRNA isolated from hypersensitive and normal responsive cells that were either untreated or treated with KP1339 for 3 h and 6 h. Subsequent bioinformatic analysis of the gained data indicated that while hypersensitive cell lines activated pathways indicative for response to chemical stimuli (“metal ion”, “organic compound”), in normal responsive ones preferentially genes involved in pathways controlling cell cycle, DNA repair and metabolism were found. Subsequent investigations confirmed that upon KP1339-treatment hypersensitive cell lines showed pronounced apoptosis induction (indicated by caspase-mediated PARP cleavage and appearance of apoptotic nuclei visualized by DAPI staining). In contrast, normal responsive cells rather reacted with prolonged duration of the G2 phase to KP1339 treatment (video evaluation). This was confirmed by FACS analysis of ethanol-fixed and propidium iodide-stained cells indicating a profound increase in the percentage of cells with double DNA content upon KP1339 treatment. Moreover, in accordance to previous studies, KP1339 induced strong phosphorylation of ERK, p38 and JNK especially in normal responsive cell lines. This is of interest as p38 and JNK activation are known to be pro-survival factors within the extrinsic pathway of apoptosis. The relevance of this particular pathway is supported by preliminary results of activation of caspase 8 upon KP1339 treatment in hypersensitive cells. This knowledge can help to better understand the mechanisms underlying the promising anticancer activity of KP1339.

Citation Format: Beatrix Alte, Christine Pirker, Thomas Mohr, Kushtrim Kryeziu, Bernhard K. Keppler, Petra Heffeter, Walter Berger. Investigation of factors involved in the hypersensitivity to KP1339-treatment. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2573. doi:10.1158/1538-7445.AM2015-2573

  • ©2015 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 75 (15 Supplement)
August 2015
Volume 75, Issue 15 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 2573: Investigation of factors involved in the hypersensitivity to KP1339-treatment
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 2573: Investigation of factors involved in the hypersensitivity to KP1339-treatment
Beatrix Alte, Christine Pirker, Thomas Mohr, Kushtrim Kryeziu, Bernhard K. Keppler, Petra Heffeter and Walter Berger
Cancer Res August 1 2015 (75) (15 Supplement) 2573; DOI: 10.1158/1538-7445.AM2015-2573

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 2573: Investigation of factors involved in the hypersensitivity to KP1339-treatment
Beatrix Alte, Christine Pirker, Thomas Mohr, Kushtrim Kryeziu, Bernhard K. Keppler, Petra Heffeter and Walter Berger
Cancer Res August 1 2015 (75) (15 Supplement) 2573; DOI: 10.1158/1538-7445.AM2015-2573
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - DNA Damaging and Antimitotic Agents and Cytotoxicity Modulators

  • Abstract 2576: Enhanced antitumor efficacy by sequential application of Wnt pathway antagonists in combination with taxanes
  • Abstract 2567: Cabazitaxel chemotherapy targets mitotic kinesins resulting in multi-nucleation of prostate cancer cells: A novel mechanism of cross-resistance with antiandrogens in advanced CRPC
  • Abstract 2565: Aryl hydrocarbon receptor agonist 5F 203 induces oxidative stress triggering DNA damage and cytoglobin up-regulation in human breast cancer cells
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement